What is Vesugen being researched for?

Vesugen is identified as KED, a synthetic Lys-Glu-Asp tripeptide in the Khavinson short peptide bioregulator group. The source describes it as being researched for vascular, circulation, and neuroprotective contexts, while also noting that it is not an approved drug and has no registered human clinical trials in the supplied evidence.

How is Vesugen proposed to work?

The supplied source attributes a gene-regulation hypothesis to the Khavinson group. In that model, KED is proposed to interact with promoter regions and influence genes discussed in vascular or neuroplasticity contexts, including CASP3, APOE, GAP43, and SOD2. The same source characterizes this as a hypothesis supported by in-vitro and docking work, not an independently settled mechanism.

Is Vesugen FDA approved?

No. The supplied evidence states that Vesugen is not FDA approved. It is described as preclinical research, with a separate source note that it is approved in Russia as a supplement.

What side effects or safety limitations are reported?

The source lists Vesugen as generally well tolerated, but also notes limited safety data outside Russia. The lack of FDA approval is a regulatory status point rather than a side effect, but it is relevant to safety review because it indicates the supplied evidence does not establish an FDA-reviewed safety profile.

What dose has been reported in the source?

The source reports 10-20 mg daily as a community-reported amount, with once- or twice-daily frequency and oral capsule or sublingual administration. This profile records that as source-reported information only, not as medical advice or an approved dosing recommendation.

Bioregulators Preclinical - animal studies only

Vesugen

Also known as: Lys-Glu-Asp, KED

At a glance

PeptiGuide dataset · reviewed Aug 2026

What it is

KED short peptide bioregulator studied mainly in preclinical vascular and neuroprotective research.

Status

Preclinical

Evidence level: animal studies

Typical dose

10–20mg

Oral capsules or sublingual

Researched for

Vascular health, blood vessel support, circulation

Trial progress

PrePreclinical
IPhase I
IIPhase II
IIIPhase III
IVPhase IV
FDAFDA approved

Preclinical - Promising animal research, limited human data

Use the tools

In plain language

Synthetic tripeptide identified as Lys-Glu-Asp, also called KED.
Categorized in the source as a Khavinson-family short bioregulator.
Researched for vascular health, blood vessel support, circulation, and neuroprotective contexts.
Evidence status is ; the supplied source reports no registered human clinical trials.
Not FDA approved; the source separately reports approval in Russia as a supplement.
Source-reported dosing information lists 10-20 mg daily, once or twice daily, by oral capsule or sublingual routes.

How it's thought to work

Vesugen is described as KED, a short cytogen-class . The proposed mechanism in the supplied source is an epigenetic gene-expression model from the Khavinson group: KED is hypothesized to interact with promoter regions and affect expression patterns involving genes such as CASP3, APOE, GAP43, and SOD2. The source frames this as supported by in-vitro and molecular-docking work, not as a broadly established receptor-mediated mechanism or clinical consensus.

What the research shows

Where the research stands

The supplied research summary emphasizes non-human evidence. It reports data from a 5xFAD transgenic Alzheimer's mouse model in which KED was associated with mushroom dendritic spine density moving toward control values after intraperitoneal dosing at 400 micrograms per kg, with related hippocampal cell-culture findings. For vascular claims, the source points mainly to Russian in-vitro and observational material and states that registered human trials have not confirmed those effects. Vascular efficacy should therefore be treated as preliminary based on the provided evidence.

What it shows

✓ Animal studies

Promising animal research, limited human data

△ Limitations

Animal study doses may not translate directly to humans.

Bottom line: Preclinical research; reported as approved in Russia as a supplement Not FDA approved

Typical dosing

CommunityCommunity dataset

10–20 mg

daily

10 mgfull range seen20 mg

Community-reported use frames Vesugen as a vascular bioregulator within the Khavinson peptide system. This is not dosing guidance and is not evidence of clinical efficacy.

Research dosing

Animal studies onlyAnimal studies only - may not translate to humans

Doses observed in studies

10-20 mg daily

Animal study doses may not translate directly to humans.

Duration: 10-30 day cycles
Administration: Oral capsules or sublingual

Timing & administration

Best time to take

Morning, empty stomach

Once or twice daily

Food recommendation

Empty stomach

Why this timing?

The source links fasted timing to typical peptide bioregulator use and absorption considerations; this is source-reported timing context, not an approved administration instruction.

Possible side effects

Not everyone experiences these. Individual responses vary with dose, duration, and personal factors.

Generally well tolerated
Limited safety data outside Russia
Not FDA approved

Not everyone experiences side effects, and severity can vary by context, purity, route, and individual health factors.

Sources

PubMed ClinicalTrials.gov FDA.gov

Frequently asked questions

Sequence

H-Lys-Glu-Asp-OH (KED)

One open dataset

Every fact on this page - doses, side effects, references - comes from the same PeptiGuide dataset that powers the Tracker, Compare, and the Lab.

Browse the dataset

Save to my research list Get updates on Vesugen

Educational resource, not medical advice. Talk to your clinician before acting on anything here.

Community discussion

Comments are moderated before they appear. Keep it evidence-focused.

Vesugen

In plain languageIn plain language

How it's thought to workHow it's thought to work

What the research showsWhat the research shows

Typical dosing

Research dosing

Timing & administrationTiming & administration

Possible side effectsPossible side effects

SourcesSources

Frequently asked questionsFrequently asked questions